The first study in Israel conducted at the Beilinson Hospital of the Clalit Group, the leading transplant center in the country, showed the increase in antibodies after receiving the third vaccine in heart, lung and kidney transplants.
According to Dr. Ruthi Rachmimov, Director of the Kidney Transplant Unit at Beilinson’s Transplant Department, 73% of patients who received the third vaccine developed antibodies and a response to this vaccine compared to only 35% who developed antibodies and a response to the vaccine after receiving the second vaccine. “The data is clear proof that the third vaccine works. We see a significant improvement in the response to the third vaccine in kidney transplant recipients. I recommend that everyone in the organ transplant group approach and get vaccinated,” said Dr. Rachmimov.
According to Prof. Mordechai Kramer, director of the Beilinson Lung Diseases Division, after the third vaccination, 33% of transplant recipients developed antibodies and a response to the vaccine, while 18% developed antibodies after the first two vaccinations. ‘There were no significant side effects with the vaccine other than spot pain at the injection site in some patients. There were no rejections from the vaccine, “said Prof. Kramer.
According to Dr. Tuvia Ben-Gal, director of the cardiac failure service at the cardiology department and director of the Beilinson Heart Transplant Clinic, after receiving the third vaccine, the percentage of heart transplant recipients who developed antibodies increased to 58%, compared with 31% of patients who developed antibodies after receiving the vaccine. The second. “According to preliminary findings, the third vaccine doubled the number of heart transplant recipients who developed antibodies after the vaccine. Transplant recipients are widely recommended to come and get vaccinated with the third vaccine, which saves lives,” said Dr. Ben Gal.
In contrast, in liver transplants, the data indicate a 1.5% increase in antibodies between the second and third vaccines. According to Dr. Marius Brown, director of the National Institute of Liver Diseases at Beilinson, 70% of patients who received the third vaccine developed antibodies and a response to the vaccine while only 47% of patients who developed antibodies after the first two vaccines. “Liver transplants raised the level of antibodies significantly. No significant side effects were seen. It is important that they go out to get vaccinated,” Dr. Brown said.